ASCO 2021 – Guardant shoots for the moon

ASCO 2021 – Guardant shoots for the moon

Source: 
EP Vantage
snippet: 

Yesterday brought a compound win for Guardant Health. Data presented at Asco reaffirmed the performance of its Lunar-2 liquid biopsy, which it is developing as a screen for colorectal cancer, and at the same time screening guidelines changed, potentially increasing the market for this very test.